Year All202420232022202120202019 Apr 02, 2024 Verve Therapeutics Announces Updates on its PCSK9 Program Mar 28, 2024 Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) Mar 01, 2024 Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) Feb 27, 2024 Verve Therapeutics Provides Pipeline Progress and Reports Fourth Quarter and Full Year 2023 Financial Results Feb 01, 2024 Verve Therapeutics to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference Jan 02, 2024 Verve Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference Dec 01, 2023 Verve Therapeutics Announces Closing of Public Offering of Common Stock, Full Exercise by Underwriters of Option to Purchase Additional Shares and Closing of Concurrent Private Placement Nov 28, 2023 Verve Therapeutics Announces Pricing of Public Offering of Common Stock and Concurrent Private Placement Nov 28, 2023 Verve Therapeutics Announces Proposed Public Offering of Common Stock and Concurrent Private Placement Nov 12, 2023 Verve Therapeutics Announces Interim Data for VERVE-101 Demonstrating First Human Proof-of-Concept for In Vivo Base Editing with Dose-Dependent Reductions in LDL-C and Blood PCSK9 Protein in Patients with Heterozygous Familial Hypercholesterolemia
Feb 27, 2024 Verve Therapeutics Provides Pipeline Progress and Reports Fourth Quarter and Full Year 2023 Financial Results
Feb 01, 2024 Verve Therapeutics to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
Dec 01, 2023 Verve Therapeutics Announces Closing of Public Offering of Common Stock, Full Exercise by Underwriters of Option to Purchase Additional Shares and Closing of Concurrent Private Placement
Nov 28, 2023 Verve Therapeutics Announces Pricing of Public Offering of Common Stock and Concurrent Private Placement
Nov 28, 2023 Verve Therapeutics Announces Proposed Public Offering of Common Stock and Concurrent Private Placement
Nov 12, 2023 Verve Therapeutics Announces Interim Data for VERVE-101 Demonstrating First Human Proof-of-Concept for In Vivo Base Editing with Dose-Dependent Reductions in LDL-C and Blood PCSK9 Protein in Patients with Heterozygous Familial Hypercholesterolemia
